MAKING THE PRESS
The prostate is a hormonally regulated organ and prostate cancer is reliant on androgen receptor signaling for growth. The treatment of advanced prostate cancer has thus traditionally focused on the inhibition of androgen signaling (for example through blockade of the androgen receptor, or inhibition of testosterone production). In the majority of cases, however, the prostate cancer will adapt to low androgen states and become castrate-resistant.
A message from our Chairman of the Board Roy Lamkin.
The Be the Difference Foundation presented Runway for Hope, a luncheon and fashion show benefiting Mary Crowley Cancer Research on September 26th. This speech was given by Be the Difference co-founder, Runway for Hope co-chair, and ovarian cancer survivor Lynn Lentscher.
Join Be the Difference Foundation for their inaugural luncheon and fashion show, Runway for Hope, benefitting Mary Crowley Cancer Research, Thursday, September 26, 2019, from 11:30 AM to 1:30 PM at Arlington Hall, 3333 Turtle Creek Boulevard, Dallas, TX 75219.
Tempus most recently established a collaboration with Mary Crowley Cancer Research with the objective of expanding research options for lung cancer patents. As part of the collaboration, Tempus will be a preferred provider for Mary Crowley Cancer Research to perform molecular sequencing, analysis and provide clinical support for patients diagnosed with lung cancer.
